Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lyell Immunopharma, Inc. (LYEL)
:LYEL
Holding LYEL?
Track your performance easily
LYEL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.55 - $3.26
Previous CloseN/A
Volume124.06K
Average Volume (3M)1.19M
Market Cap
$163.29M
Enterprise Value-$28.27M
Total Cash (Recent Filing)$436.05M
Total Debt (Recent Filing)$27.13M
Price to Earnings (P/E)―
Beta2.71
Next Earnings
Feb 26, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding292,161,650
10 Day Avg. Volume856,995
30 Day Avg. Volume1,185,693
Standard Deviation0.25
R-Squared0.00482
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2477.09
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.17
Enterprise Value/Revenue-448.66
Enterprise Value/Gross Profit-217.43
Enterprise Value/Ebitda0.16
Forecast
1Y Price Target
$1.87Price Target Upside222.41% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering3
Lyell Immunopharma News
PremiumCompany Announcements
Lyell Immunopharma Reports Q3 2024 Financial Results
PremiumPre-Earnings
Is LYEL a Buy, Before Earnings?
PremiumCompany Announcements
Lyell Immunopharma’s Strategic Moves and Leadership Expansion
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsInitial data of IMPT-314 in a study showed a remarkable 92% overall response rate with 77% complete responses.
Financial StabilityLyell ended with $461 million in cash, providing an operational runway into 2027.
Strategic AcquisitionThe acquisition of ImmPACT Biosciences focuses Lyell Immunopharma on a promising CAR-T cell therapy for B-cell lymphomas.
Bears Say
Competitive ChallengesCompeting with established players like Gilead, Bristol, and Novartis is likely to be challenging, especially given their sizeable infrastructure investments.
Market SaturationThe CD19-targeted CAR-T space is crowded, and the opportunity for another entrant like Lyell is limited.
Strategy UncertaintyThe decision to discontinue next-gen, early-stage, solid tumor CAR-T LYL119 adds to the uncertainty surrounding Lyell's strategy.
---
Ownership Overview
17.61% Insiders
7.82% Mutual Funds
<0.01% Other Institutional Investors
67.70% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LYEL FAQ
What was Lyell Immunopharma, Inc.’s price range in the past 12 months?
Lyell Immunopharma, Inc. lowest stock price was $0.55 and its highest was $3.25 in the past 12 months.
What is Lyell Immunopharma, Inc.’s market cap?
Lyell Immunopharma, Inc.’s market cap is $163.29M.
When is Lyell Immunopharma, Inc.’s upcoming earnings report date?
Lyell Immunopharma, Inc.’s upcoming earnings report date is Feb 26, 2025 which is in 39 days.
How were Lyell Immunopharma, Inc.’s earnings last quarter?
Lyell Immunopharma, Inc. released its earnings results on Nov 07, 2024. The company reported -$0.155 earnings per share for the quarter, beating the consensus estimate of -$0.195 by $0.04.
Is Lyell Immunopharma, Inc. overvalued?
According to Wall Street analysts Lyell Immunopharma, Inc.’s price is currently Undervalued.
Does Lyell Immunopharma, Inc. pay dividends?
Lyell Immunopharma, Inc. does not currently pay dividends.
What is Lyell Immunopharma, Inc.’s EPS estimate?
Lyell Immunopharma, Inc.’s EPS estimate is -0.18.
How many shares outstanding does Lyell Immunopharma, Inc. have?
Lyell Immunopharma, Inc. has 292,161,650 shares outstanding.
What happened to Lyell Immunopharma, Inc.’s price movement after its last earnings report?
Lyell Immunopharma, Inc. reported an EPS of -$0.155 in its last earnings report, beating expectations of -$0.195. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lyell Immunopharma, Inc.?
Among the largest hedge funds holding Lyell Immunopharma, Inc.’s share is EntryPoint Capital, LLC. It holds Lyell Immunopharma, Inc.’s shares valued at 287K.
---
Lyell Immunopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$1.87 (222.41% Upside)
$1.87 (222.41% Upside)
Blogger Sentiment
Neutral
LYEL Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 187.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 11.3%
Last 30 Days ▲ 11.3%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.25%
12-Months-Change
Fundamentals
Return on Equity
-33.22%
Trailing 12-Months
Asset Growth
-22.11%
Trailing 12-Months
Company Description
Lyell Immunopharma, Inc.
Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors.
---
LYEL Stock 12 Month Forecast
Average Price Target
$1.87
▲(222.41% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
Fate Therapeutics
―
Intellia Therapeutics
―
Editas Medicine
―
Cellectis SA
―
Best Analysts Covering LYEL
1 Year
1 Year Success Rate
2/3 ratings generated profit
1 Year Average Return
+3.03%
reiterated a sell rating 3 days ago
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +3.03% per trade.
---